Kate Somerville EradiKate Acne Mark Fading Gel: two lists and several claims

The manufacturer identifies EradiKate Acne Mark Fading Gel and describes 2% salicylic acid. Other EradiKate cleanser and spot-product names should not supply missing information for this gel. An ingredient or outcome attached to a neighboring item remains that item’s statement, even when the family name is familiar. Exact gel identity.

This is an identity question before it is an evidence question. The product-version guide explains why the actual name and format deserve to stay beside a formula declaration rather than being reduced to the brand’s acne category.

The page uses acne-mark and scars language, then discusses texture, tone, refreshed pores and a microbiome narrative. Those are the manufacturer’s advertised descriptions. They should not be collapsed into one verified endpoint or interpreted as proof that the product permanently changes pore size or corrects a particular reader’s scars. Advertised endpoint context. Marks after acne, current blemishes, skin tone and a refreshed appearance are not identical endpoint descriptions. Their proximity on a sales page does not establish that one supplied measurement covers all of them. A reader can understand the advertised scope while still recognizing the missing method for each claim.

The examined material did not supply a complete clinical report that defines each of those effects. The Paula’s Choice review provides another place to examine the relationship between an appearance headline and the specific information supporting it.

The dated label gives salicylic acid 2% an acne-treatment purpose and carries separate new-blemish wording. That field says what the label states as the product’s drug use. It does not establish every mark, tone or microbiome statement found on the sales page. Active, purpose and use.

FDA distinguishes an active ingredient and its amount from purpose, use and inactive information. That structure is useful here because the marketing narrative is broader than the label’s purpose field. FDA field explanation. The two-percent guide keeps the active figure from becoming the entire product story.

The retained website list includes Propanediol and Microcitrus Australasica. Neither appears in the complete posted label list examined here. The two lists are therefore recorded separately. A reviewer should not insert the website-only entries into the label or remove them from the website account to manufacture agreement. Website declaration. Posted inactive list. The observation is limited to the actual complete declarations examined. It is not based on guessing from an ingredient highlight or on assuming that a later posting must be the definitive package formula. A matching active percentage does not resolve a disagreement elsewhere in the base.

The discrepancy does not reveal which base is in a particular container. No package inspection resolved it. The Murad cleanser review offers a different version-reading question without contributing its ingredients or history to this gel.

The December 2025 Rare Beauty Brands record uses NDC 72204-903 and names the gel. That identity is useful alongside the two ingredient accounts because it specifies which posted label is being compared. The date belongs to the record, not an observed manufacturing event or a verified current shipment. Named label and package. The posted labeler name is part of the record’s identity. It does not describe a professional consultation with the reader or an independent review conducted by this publication. Keeping the labeler, product and date together is a practical way to distinguish one official record from another.

Current price, stock and delivery were not freshly tested for this review. Keeping that transaction gap explicit avoids making an identity match do the work of fulfillment evidence. The supply-term guide explains why those questions remain separate.

FDA explains that cosmetic claims must be truthful and not misleading, while disease-treatment or body-function purposes bring drug requirements. That framework helps distinguish the gel’s appearance advertising from its posted acne purpose. It is not a finding that this exact product or any particular sentence complies or fails to comply with those requirements. FDA claim-purpose framework. Gel appearance claims.

The review consequently reports the wording and its limits. A clear explanation of those roles is more useful than supplying a legal verdict or treating every attractive appearance claim as a demonstrated clinical effect.

The manufacturer material and the posted label retain relevant drying cautions. Those cautions remain part of the gel’s record even when the surrounding sales language emphasizes a more even-looking complexion. Neither document, by itself, provides personal clearance or settles the ingredient-list discrepancy. Website context. Label cautions. The outstanding formula question remains useful even without a performance conclusion. It can be stated plainly: the two records do not list exactly the same base, and no inspected package resolved which declaration describes a particular supplied item.

The useful description is bounded: a named 2% acne-mark gel, a dated acne label, separate appearance advertising and two nonmatching declarations. Application instructions, a personal routine and a claimed firsthand outcome do not follow from that documentary account.